Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Brian Faherty"'
Autor:
Vijay Sivaraman, Michael G. Hudgens, Eliane Rohner, Anna Baker, Siobhan O'Connor, Sean M. Gregory, Claire Edelman, Brian Faherty, Lisa Rahangdale, John W. Schmitt, Busola Sanusi, Julie A. E. Nelson, Kirsty Chesko, Jennifer S. Smith, Andrea K. Knittel, LaHoma S. Romocki
Publikováno v:
Cancer Epidemiol Biomarkers Prev
Background: Primary high-risk human papillomavirus (hr-HPV) testing of self-collected cervico-vaginal swabs could increase cervical cancer screening coverage, although triage strategies are needed to reduce unnecessary colposcopies. We evaluated the
Autor:
Lisa Rahangdale, Kirsty Chesko, Vijay Sivaraman, Samantha E. Tulenko, Eliane Rohner, Brian Faherty, Jennifer S. Smith, Busola Sanusi, John W. Schmitt, Laurence M. Vaughan, Julie A. E. Nelson, LaHoma S. Romocki, Andrea K. Knittel
Publikováno v:
J Clin Microbiol
The objective was to assess the diagnostic test accuracy of high-risk human papillomavirus (hrHPV) testing of self-collected urine and cervicovaginal samples for the detection of cervical intraepithelial neoplasia grade 2 or higher (CIN2+). We recrui
Autor:
Ido Ben-Zvi, Ido Sloma, Brian Faherty, Piotr T. Wysocki, Elizabeth Bruckheimer, David Sidransky, Gilson Baia, Luciane T. Kagohara, Elana J. Fertig, D. Ciznadija, Evgeny Izumchenko, Mariana Brait, Keren Paz, Tin Oo Khor, Samuel Long
Publikováno v:
British Journal of Cancer
Background: Screening of patients for cancer-driving mutations is now used for cancer prognosis, remission scoring and treatment selection. Although recently emerged targeted next-generation sequencing-based approaches offer promising diagnostic capa
Autor:
William A. Nussbaumer, Laurence M. Vaughan, Ryan J. Schwab, Erin C. Gutierrez, James M. Harris, Brian Faherty
Publikováno v:
Human Papillomavirus-Research in a Global Perspective
Cervical cancer screening has been one of the most impactful human interventions in medical history, saving the lives of countless thousands of women since the introduction of organized cytology screening programs. Today, we stand at a crossroads in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18e1d4c22c1e66b7b6da8cc384765a91
http://www.intechopen.com/articles/show/title/cervical-cancer-screening-at-a-crossroads-learnings-from-the-past-driving-change-for-the-future
http://www.intechopen.com/articles/show/title/cervical-cancer-screening-at-a-crossroads-learnings-from-the-past-driving-change-for-the-future
Autor:
David Sidransky, Ido Sloma, Piotr J. Wysocki, Daniel Ciznadija, Elana J. Fertig, Elizabeth Bruckheimer, Tin Oo Khor, Mariana Brait, Luciane T. Kagohara, Evgeny Izumchenko, Keren Paz, Gilson Baia, Ido Ben-Zvi, Samuel Long, Brian Faherty
Publikováno v:
Cancer Research. 76:3640-3640
Screening of patients for cancer-driving mutations is now used for cancer prognosis, remission scoring and treatment selection. Although recently emerged targeted Next Generation Sequencing (NGS) - based approaches provide accurate results and offer